Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).
Posted by SkinDoc on Saturday, November 7, 2009, at 8:40 am. Filed under Skin Care News. Tagged Adults, Antibacterial, Bacterial Infections, Clinical Trial, Discovery, Global Problem, Microbial Resistance, Novel Antibiotics, Oral, Pharmaceutical Company, Phase Ii, Skin And Skin, Skin Infections, Skin Structure Infections.
Both comments and trackbacks are currently closed.
